The activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
Activist investor Starboard Value said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose the drug-maker's acquisition of Celgene.
Smith argued that Starboard was"surprised" to hear of the proposed acquisition on the heels of what he characterized as poor financial and stock price performance over the last few years.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition
Read more »
Top Bristol-Myers shareholder comes out against $74 billion Celgene dealBristol-Myers Squibb Co's top shareholder Wellington Management said on Wed...
Read more »
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers Squibb Co.'s $74 billion takeover of Celgene is in jeopardy after the former's second-largest shareholder has turned against it.
Read more »
Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition
Read more »
Top Bristol-Myers shareholder comes out against $74 billion Celgene dealBristol-Myers Squibb Co's top shareholder Wellington Management said on Wed...
Read more »
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers Squibb Co.'s $74 billion takeover of Celgene is in jeopardy after the former's second-largest shareholder has turned against it.
Read more »
Value investor Greenblatt says market in expensive range historically, likes Home Depot, Boeing
Read more »